Emtricitabine / Tenofovir — Competitive Intelligence Brief

Emtricitabine / Tenofovir (Emtricitabine / Tenofovir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination. Area: Infectious Disease / Virology.

marketed Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Emtricitabine / Tenofovir (Emtricitabine / Tenofovir) — The Miriam Hospital. Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Emtricitabine / Tenofovir TARGET	Emtricitabine / Tenofovir	The Miriam Hospital	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
Sofosbuvir, Ribavirin, and Stribild	Sofosbuvir, Ribavirin, and Stribild	Saint Michael's Medical Center	marketed	Direct-acting antiviral (DAA) combination; antiretroviral combination	HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
AZT	AZT	Johns Hopkins Bloomberg School of Public Health	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
"Raltegravir" and "Zidovudine"	"Raltegravir" and "Zidovudine"	Universidad Peruana Cayetano Heredia	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitor)	HIV integrase (raltegravir); HIV reverse transcriptase (zidovudine)
Abacavir sulfate, Lamivudine and Zidovudine	Abacavir sulfate, Lamivudine and Zidovudine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Vaginal TFV Gel	Vaginal TFV Gel	University of Washington	marketed	Nucleotide reverse transcriptase inhibitor (microbicide)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination class)

1. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
2. Bristol-Myers Squibb · 1 drug in this class
3. Puerto Rico Community Network for Clinical Research on AIDS · 1 drug in this class
4. The Miriam Hospital · 1 drug in this class